NCT02245347

Brief Summary

Drug resistant tuberculosis is a growing problem world wide. The current methods for diagnosis are time consuming and may delay diagnosis and treatment for many weeks. In this study the investigators wish to take sputum samples from patients to see if the investigators can validate a molecular DNA based process for prompt identification of drug resistant tuberculosis. The investigators wish to extract and amplify DNA from drug resistant tuberculosis and identify genes within it that confer resistance.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2013

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

September 12, 2014

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 19, 2014

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2016

Completed
Last Updated

September 19, 2014

Status Verified

September 1, 2014

Enrollment Period

3 years

First QC Date

September 12, 2014

Last Update Submit

September 17, 2014

Conditions

Keywords

TBTuberculosisMDR TBDrug resistant TB

Outcome Measures

Primary Outcomes (1)

  • Identification and sequencing of mycobacterial DNA from sputum samples

    To see if mycobacterial DNA can be identified and sequenced from sputum and if the results correlate with the Microtiter Plate Methods done phenotypically in the standard manner.

    within 24 hours of sample collection

Study Arms (1)

Patients with expected MDR TB

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Smear positive patients with confirmed or suspected TB

You may qualify if:

  • Any patient with smear positive tuberculosis who is capable to give informed consent will be offered to be included in the trial.

You may not qualify if:

  • Any patient under 18 or who is unable to give informed consent will be excluded from this trial. Any patient who is unable to give a sputum sample.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

St George's NHS Healthcare Trust

London, SW180RE, United Kingdom

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Sputum samples

MeSH Terms

Conditions

TuberculosisTuberculosis, Multidrug-Resistant

Condition Hierarchy (Ancestors)

Mycobacterium InfectionsActinomycetales InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfections

Central Study Contacts

Catherine Cosgrove, MBBS

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 12, 2014

First Posted

September 19, 2014

Study Start

April 1, 2013

Primary Completion

April 1, 2016

Last Updated

September 19, 2014

Record last verified: 2014-09

Locations